London,UK (PRWEB) October 01, 2013
Targeting unmet needs in treating hematological malignances through the development of innovative drugs has witnessed considerable achievements recently. Over the past 10 years, proteasome inhibitor Velcade (Bortezomib) and the immunomodulatory drugs such as Revlimid (lenalidomide) and Thalomid (thalidomide) have become the basic treatments for multiple myeloma (MM) leading to the improvement in survival rates. Nevertheless, new treatment options for relapsed/refractory multiple myeloma (RRMM) are required to further improve survival and the quality of life of this group patients, and new drugs, such as Kyprolis (carfilzomib) or Pomalyst (pomalidomide, Imnovid), have already started to successfully fulfill this need.
The ever increasing need for innovative therapies for unmet needs/challenging diseases spurs the pace of drug development, either directly or through partnership/in-licensing. Meantime, maturing pipeline, successful launches and new drug approvals sustain the growth trajectory of the biotech companies.
In-demand research report “Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A” drawn up by MP Advisors has been recently published by Market Publishers Ltd.
Title: Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A
Published: September, 2013
Price: US$ 2,500.00
The report offers an insightful overview of the therapies for multiple myeloma (including newly diagnosed – NDMM and relapsed/refractory – RRMM). It sheds light on the unmet needs and limitations of the current standard of care for relapsed and refractory MM patients. It describes the competitive scenario and delivers information on the leading biotech companies, covering clinical data of drugs, milestones, and valuation; indicates commercial opportunity in pursuing this therapy area. The research study reviews the early- and late-stage drugs in the clinic, covers key mergers and acquisitions in the area, provides clinical trial details of key drugs in pipeline, and offers an au-close look at the future of the drugs in the late-stage pipeline.
- Comprehensive disease profile, review of unmet needs and description of the current standard of care.
- Extensive overview of the therapies for multiple myeloma (including newly diagnosed – NDMM and relapsed/refractory – RRMM).
- Data on the drugs in the pipeline: NDMM & RRMM – mechanism of action (MoA) and clinical stage of development.
- Clinical trial details of key drugs in pipeline.
- Discussion of the important issues related to the therapeutic area.
- Information on M&A and licensing deals that have taken place over the past five years.
- Evaluation of in-licensing and/or M&A opportunities.
- Insights into the competitive environment and detailed company profiles.
- Future outlook.
More new research reports by the publisher can be found at MP Advisors page.